Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US).

被引：0

作者：

Tran, Nguyen H.

Soefje, Scott A.

Rangarajan, Nivedita

Purushotham, K.

Nadig, Mihika

Wagner, Tyler E.

Valerio, Stephen J.

Anderson, Rye

Olson, Jody C.

机构：

[1] Mayo Clin Rochester, Dept Oncol, Rochester, MN USA

[2] Mayo Clin, Dept Pharm, Rochester, MN USA

[3] Nference Inc, Cambridge, MA USA

[4] US Oncol Med Affairs AstraZeneca, Gaithersburg, MD USA

[5] AstraZeneca, US Oncol Care & Access, Gaithersburg, MD USA

[6] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA

来源：

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.572

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：572 / 572

页数：1